title: Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT.
abstract: To analyze the outcome of solid organ transplantation (SOT) in patients who had undergone allogeneic hematopoietic stem cell transplantation (HSCT), a questionnaire survey was carried out within 107 European Group of Blood and Marrow Transplantation centers. This study covered HSCT between 1984 and 2007 in Europe. Forty-five SOT in 40 patients were reported. Fifteen liver, 15 renal, 13 lung, 1 heart and 1 skin transplantations were performed in 28 centers. Overall survival (OS) of patients after SOT was 78% at 5 years (95% confidence interval [CI], 64% to 92%). OS at 5 years was 100% for renal, 71% (95% CI, 46% to 96%) for liver and 63% (95% CI, 23% to 100%) for lung transplant recipients. The 2-year-incidence of SOT failure was 20% (95% CI, 4% to 36%) in patients with graft-versus-host disease (GvHD) and 7% (95% CI, 0% to 21%) in patients without GvHD before SOT. The relapse incidence for underlying malignant diseases was 4% at 5 years (95% CI, 0% to 12%). In summary, this study shows that selected patients receiving SOT after HSCT have a remarkably good overall and organ survival. These data indicate that SOT should be considered in selected patients with single organ failure after HSCT.
authors.affiliation: Hannover Medical School, Department of Hematology, Hemostasis, Hannover, Germany. koenecke.christian@mh-hannover.de
authors.forename: C
authors.initials: C
authors.lastname: Koenecke
authors.forename: B
authors.initials: B
authors.lastname: Hertenstein
authors.forename: J
authors.initials: J
authors.lastname: Schetelig
authors.forename: A
authors.initials: A
authors.lastname: van Biezen
authors.forename: E
authors.initials: E
authors.lastname: Dammann
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: M
authors.initials: M
authors.lastname: Schleuning
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: N
authors.initials: N
authors.lastname: Jacobsen
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: T
authors.initials: T
authors.lastname: de Witte
authors.forename: T
authors.initials: T
authors.lastname: Ruutu
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005060:Europe / Q000453:epidemiology; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects* / Q000401:mortality; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis